References in periodicals archive ?
Febuxostat is another xanthine oxidase inhibitor that is used to lower uric acid.
Members of the Food and Drug Administration's Arthritis Advisory Committee have voted in favor of recommending approval of the investigational uricosuric drug lesinurad at 200 mg daily for the proposed indication of treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor, such as allopurinol or febuxostat.
Drugs profiles discussed in this report includes arhalofenate, febuxostat, febuxostat XR, JPH-367, KGO-2142, KGO-2173, KUX-1151, LC-350189, NC-2500, pegadricase, RDEA-3170, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia, XEN-102.
Febuxostat is an alternative, and a newer drug, lesinurad, is still awaiting NICE approval.
Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
One of these very potent new compounds is febuxostat [13], a non-purine inhibitor of XO that has a favorable toxicology profile, high bioavailability, more potent and longer-lasting hyperuricemia action than allopurinol [14].
The TFP recommended that initial therapy to lower serum urate should consist of a xanthine oxidase inhibitor, either allopurinol or febuxostat, with no preference asserted.
Allopurinol and febuxostat, urate lowering drugs, bring hyperuricemia under control by decreasing urate production, which allows for the recycling of urate deposits.
This edition has 200 new monographs, new and updated interactions advice, and the addition of drugs like febuxostat, ivabradine, lacosamide, pitavastatin, retigabine (ezogabine), rufinamide, and ulipristal.
There are currently five drugs that can be used to treat gout: allopurinol (Zyloprim), colchicine (Colcrys), febuxostat (Uloric), pegloticase (Krys-texxa), and probenecid.
Besides the newly developed and licensed synthetic XO-inhibitor febuxostat (Baker and Schumacher 2010), only a few ethnopharmacological approaches have been described (Cos et al.
Therapeutic use: Febuxostat (16, 17) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.